A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging
Abstract Background Elacestrant is an oral selective estrogen receptor (ER) degrader. This phase 1b open-label, non-randomized study (RAD1901-106) was initiated to determine the effect of elacestrant on the availability of ER in lesions from postmenopausal women with ER+ advanced breast cancer (ABC)...
Main Authors: | Agnes Jager, Elisabeth G. E. de Vries, C. Willemien Menke-van der Houven van Oordt, Patrick Neven, Clasina M. Venema, Andor W. J. M. Glaudemans, Yamei Wang, Rebecca G. Bagley, Maureen G. Conlan, Philippe Aftimos |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-09-01
|
Series: | Breast Cancer Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13058-020-01333-3 |
Similar Items
-
Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors
by: Hitisha K. Patel, et al.
Published: (2019-12-01) -
Enhanced pulmonary uptake on 18F-FES-PET/CT scans after irradiation of the thoracic area: related to fibrosis?
by: C. M. Venema, et al.
Published: (2019-08-01) -
PET Imaging Agents (FES, FFNP, and FDHT) for Estrogen, Androgen, and Progesterone Receptors to Improve Management of Breast and Prostate Cancers by Functional Imaging
by: John A. Katzenellenbogen
Published: (2020-07-01) -
Visual and quantitative evaluation of [18F]FES and [18F]FDHT PET in patients with metastatic breast cancer: an interobserver variability study
by: Lemonitsa H. Mammatas, et al.
Published: (2020-04-01) -
The Vienna FES Interview Protocol – A mixed-methods protocol to elucidate the opinions of various individuals responsible for the provision of FES exercise
by: Matthew J. Taylor, et al.
Published: (2017-08-01)